D.R. Horton’s Index Removal and Softer Trends Could Be A Game Changer For DHI

D.R. Horton, Inc.

D.R. Horton, Inc.

DHI

0.00

  • In August 2026, D.R. Horton, Inc. was removed from the Philippines All Share Index after a period of softer quarterly results, declining backlog and orders, and a marked reduction in return on invested capital.
  • This combination of weaker operating trends and loss of index inclusion highlights mounting questions about the homebuilder’s ability to sustain prior levels of profitable growth and new business momentum.
  • We’ll now examine how D.R. Horton’s weaker backlogs and index removal may reshape the previously optimistic investment narrative around housing demand.

Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

D.R. Horton Investment Narrative Recap

To own D.R. Horton today, you need to believe its scale and focus on entry-level buyers can still convert housing demand into solid cash generation, despite recent pressure on orders, margins, and returns. The loss of Philippines All Share Index inclusion and softer results sharpen the near term focus on whether backlogs stabilize; the biggest current risk is that ongoing affordability issues and higher incentives keep chipping away at profitability.

The latest quarterly earnings on 21 July 2026 are especially relevant here, as they showed year over year declines in sales and net income despite still-large revenue, reinforcing concerns that weaker orders and returns on invested capital are not just a blip. Combined with the sizable ongoing buybacks and steady dividend, these results frame a tension between capital returned to shareholders and questions about the durability of D.R. Horton’s underlying earnings power.

Yet behind the headline index removal, one risk investors should be aware of is how rising incentives and flat pricing could quietly reshape D.R. Horton’s margin profile...

D.R. Horton’s narrative projects $42.4 billion revenue and $4.4 billion earnings by 2029. This requires 8.3% yearly revenue growth and about a $1.2 billion earnings increase from $3.2 billion today.

Uncover how D.R. Horton's forecasts yield a $165.29 fair value, a 9% upside to its current price.

Exploring Other Perspectives

DHI 1-Year Stock Price Chart
DHI 1-Year Stock Price Chart

While recent index removal raises fresh questions about margins and demand, the most optimistic analysts were, before this news, projecting revenue of about US$44.5 billion and earnings near US$4.9 billion, which is far more upbeat than the baseline narrative around weaker orders and rising incentives. This wide gap in expectations shows how differently you can interpret the same business, and why it can be helpful to compare several viewpoints before deciding what you believe.

Explore 4 other fair value estimates on D.R. Horton - why the stock might be worth 17% less than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

  • A great starting point for your D.R. Horton research is our analysis highlighting 2 key rewards that could impact your investment decision.
  • Our free D.R. Horton research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate D.R. Horton's overall financial health at a glance.

Searching For A Fresh Perspective?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

  • Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
  • The future of work is here. Discover the 38 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
  • AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.